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Abstract
Homozygosity has long been associated with rare, often devastating, Mendelian disorders1 and 
Darwin was one of the first to recognise that inbreeding reduces evolutionary fitness2. However, 
the effect of the more distant parental relatedness common in modern human populations is less 
well understood. Genomic data now allow us to investigate the effects of homozygosity on traits 
of public health importance by observing contiguous homozygous segments (runs of 
homozygosity, ROH), which are inferred to be homozygous along their complete length. Given 
the low levels of genome-wide homozygosity prevalent in most human populations, information is 
required on very large numbers of people to provide sufficient power3,4. Here we use ROH to 
study 16 health-related quantitative traits in 354,224 individuals from 102 cohorts and find 
statistically significant associations between summed runs of homozygosity (SROH) and four 
complex traits: height, forced expiratory lung volume in 1 second (FEV1), general cognitive 
ability (g) and educational attainment (nominal p<1 × 10−300, 2.1 × 10−6, 2.5 × 10−10, 1.8 × 
10−10). In each case increased homozygosity was associated with decreased trait value, equivalent 
to the offspring of first cousins being 1.2 cm shorter and having 10 months less education. Similar 
effect sizes were found across four continental groups and populations with different degrees of 
genome-wide homozygosity, providing convincing evidence for the first time that homozygosity, 
rather than confounding, directly contributes to phenotypic variance. Contrary to earlier reports in 
substantially smaller samples5,6, no evidence was seen of an influence of genome-wide 
homozygosity on blood pressure and low density lipoprotein (LDL) cholesterol, or ten other 
cardio-metabolic traits. Since directional dominance is predicted for traits under directional 
evolutionary selection7, this study provides evidence that increased stature and cognitive function 
have been positively selected in human evolution, whereas many important risk factors for late-
onset complex diseases may not have been.
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Inbreeding influences complex traits through increases in homozygosity and corresponding 
reductions in heterozygosity, most likely resulting from the action of deleterious (partially) 
recessive mutations8. For polygenic traits, a systematic association with genome-wide 
homozygosity is not expected when dominant alleles at some loci increase the trait value 
while others decrease it. Rather, dominance must be biased in one direction on average over 
all causal loci, for instance to decrease the trait. Such directional dominance is expected to 
arise in evolutionary fitness-related traits due to directional selection8. Studies of genome-
wide homozygosity thus have the potential to reveal the non-additive allelic architecture of a 
trait and its evolutionary history. Historically inbreeding has been measured using 
pedigrees9. However, such techniques cannot account for the stochastic nature of 
inheritance, nor are they practical for the capture of the distant parental relatedness present 
in most modern day populations. High density genome-wide single nucleotide 
polymorphism (SNP) array data can now be used to assess genome-wide homozygosity 
directly, using genomic runs of homozygosity (ROH). Such runs are inferred to be 
homozygous-by-descent and are common in human populations10-11. SROH is the sum of 
the length of these ROH, in megabases of DNA. FROH is the ratio of SROH to the total 
length of the genome. Like pedigree-based F (with which it is highly correlated3), FROH 
estimates the probability of being homozygous at any site in the genome. FROH has been 
shown to vary widely within and between populations12 and is a powerful method of 
detecting genome-wide homozygosity effects13.
We found marked differences by geography and demographic history in both the population 
mean SROH and the relationship between SROH and NROH (the numbers of separate runs 
of homozygosity). (Fig. 1). As observed previously3,12,14, isolated populations have a higher 
burden of ROH whereas African heritage populations have the least homozygosity.
We studied βFROH, defined as the effect of FROH on 16 complex traits of biomedical 
importance (Fig. 2). For height, FEV1 (forced expiratory volume in one second, a measure 
of lung function), educational attainment (EA) and g (a measure of general cognitive ability 
derived from scores on several diverse cognitive tests), we found the effect sizes were 
greater than two intra-sex standard deviations (SD), with p-values all less than 10−5. Thus 
the associations could not plausibly be explained by chance alone (Table 1; see Extended 
data Figs. 1-4 for Forest plots of individual traits; Supplementary Table 1 for SD). To ensure 
that the results were not driven by a few outliers, we repeated the analysis excluding 
extreme sub-cohort trait results. In all cases the effect sizes and their significance remained 
similar or increased (see Supplementary Table 2 for comparisons with and without outliers). 
After exclusion of outliers, these effect sizes translate into a reduction of 1.2 cm in height 
and 137 ml in FEV1 for the offspring of first cousins, and into a decrease of 0.3 SD in g and 
10 months less educational attainment.
We performed a number of analyses to exclude confounding. Whilst SROH is wholly a 
genetic effect, its inheritance is entirely non-additive. Therefore, unlike in genome-wide 
association, an association with population genetic structure or co-segregation of additive 
genome-wide polygenic effects and SROH (as opposed to SNPs in a GWAS) are not 
expected as a matter of course, except in the case of siblings. However, confounding could 
still theoretically arise as discussed below. We therefore assessed this by conducting 
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stratified and covariate analyses. We found effects of similar magnitude and in the same 
direction for all four traits across isolated and non-isolated European, Finnish, African, 
Hispanic, East Asian and South and Central Asian populations (Extended Data Fig. 5a, 
Supplementary Table 3). We further tested whether the effect sizes were similar when 
cohorts were split into more and less homozygous groups. The effect sizes were very similar 
even though the degree of homozygosity (and variation in homozygosity) varied 3-10-fold 
between the two strata (depending on which cohorts contributed to the trait; Extended Data 
Fig. 5b). This suggests a broadly linear relationship with SROH. In general confidence 
intervals overlap for stratified estimates, suggesting differences arose due to sampling 
variance. Larger confidence intervals for some estimates reflect the lower power of some 
strata, in turn reflecting the sample size and degree of homozygosity of those strata (e.g. the 
wider confidence intervals for estimates of Educational Attainment βFROH for Finnish and 
African strata). Finally, we fitted educational attainment as a proxy for potential 
confounding by socio-economic status; this covariate was available in sufficient (47) cohorts 
to maintain power. The estimated effect sizes for height, FEV1 and g all reduced (17%, 18% 
and 35%, Fig. Extended Data Fig. 5c), but this might have been expected given the known 
covariance between these three traits and EA, and the association we found between 
educational attainment and FROH. We found very small differences (3-11% reductions) in 
estimated βFROH (Extended Data Fig. 6, supplementary table 4), when comparing the fitting 
of polygenic mixed models as opposed to fixed-effect-only models, again suggesting that 
confounding (in this case due to polygenic effects due to recent common ancestry) was not 
substantially affecting the results.
Despite the observed 17-35% reductions in estimated effect sizes for FROH on height, FEV1 
and g, when fitting educational attainment as a covariate, the persistence of an effect 
suggests that most of the signals we observe are genetic. The consistency of effects with and 
without fitting relatedness and in particular in populations with very different degrees of 
homozygosity, all appear inconsistent with confounding due to environmental or additive 
genetic effects. As does the broad similarity in effect sizes across continents, although the 
relatively smaller numbers of cohorts of non-European descent meant we had limited power 
to detect inter-continental differences in effect sizes.
It is also interesting to consider the potential influence of assortative mating, which is 
commonly observed for human stature, cognition and education. The phenotypic extremes 
could be more genetically similar to each other and hence the offspring more homozygous, 
even if the highly polygenic trait architectures reduce this effect. However, at least in its 
simplest balanced form, the increase in genetic similarity would be equal at both ends of the 
phenotypic distribution, leading to no linear association between such genetic similarity and 
the trait; both tall and short people would be more homozygous. Furthermore, humans also 
mate assortatively on body mass index (BMI), for which we see no effect. A more complex 
possibility, a form of reverse-causality, could arise when subjects from one trait extreme 
(e.g. more educated people) are on average more geographically mobile, and thus have less 
homozygous offspring, with those offspring in turn inheriting the trait extreme concerned15. 
We do not think that this mechanism can account for our results, since it does not readily 
explain the constancy of our results under different models, especially the similarity in 
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βFROH for either more or less homozygous populations. Moreover, we observe similar 
effects in multiple single village cohorts, and the Amish and Hutterites, where there is no 
geographic structure and/or no sampling of immigrants, hence such confounding by 
differential migration cannot occur.
Our estimate for the effect of homozygosity in height is consistent with previous work: 
genomic4 and pedigree16 studies have shown genome-wide homozygosity effects on stature 
with similar effect sizes (0.01 increase in F decreases height by 0.037 SD16 versus 0.029 SD 
in the present study). We speculate that homozygosity is acting on a shared endophenotype 
of torso size which we detect in the height and FEV1 traits. The fact that the FEV1/FVC 
(forced vital capacity) ratio is not associated with ROH points to the effect being on lung/
chest size rather than airway calibre. The cognition effects cannot be wholly generated by 
height as an intermediate cause, given the greater proportion of variance explained for 
cognition, although we note that the correlation between height and cognition is 0.16 (SE 
0.01), and the genetic correlation (the correlation in additive genetic values) is 0.28 (SE 
0.09; ref 17). Height is the canonical human complex trait, highly heritable and polygenic, 
with 697 genome-wide significant variants in 423 loci explaining 20% of the heritability and 
all common variants predicted to explain 60% of the heritability18. Most of the genetic 
architecture appears to be additive in nature, however ROH analysis reveals a distinct 
directional dominance component.
Our genomic confirmation of directional dominance for g and discovery of genome-wide 
homozygosity effects on educational attainment in a wide range of human populations adds 
to our knowledge of the genetic underpinnings of cognitive differences, which are currently 
thought to be largely due to additive genetic effects19. Our findings go beyond earlier 
pedigree-based analyses of recent consanguinity to demonstrate that the observed effect of 
genome-wide homozygosity is not a result of confounding and influences demographically 
diverse populations across the globe. The estimated effect size is consistent with pedigree 
data (0.01 increase in F decreases g by 0.046 SD in our analysis and 0.029-0.048 SD in 
pedigree-based studies)20. It is germane to note that one extreme of cognitive function, early 
onset cognitive impairment, is strongly influenced by deleterious recessive loci21, so we can 
speculate that an accumulation of recessive variants of weaker effect may influence normal 
variation in cognitive function. Although increasing migration and panmixia have generated 
a secular trend in decreasing homozygosity22, the Flynn effect, wherein succeeding 
generations perform better on cognitive tests than their predecessors23, cannot be explained 
by our findings, because the intergenerational change in cognitive scores is much larger than 
the differences in homozygosity would predict. Likewise, the genome-wide homozygosity 
effect on height cannot explain a significant proportion of the observed inter-generational 
increases24.
Inbreeding depression, which arises from the effect of genome-wide homozygosity, is 
ubiquitous in plants and is seen for numerous fitness-related traits in animals25, but we 
observed no effect for the 12 other mainly cardio-metabolic traits in which variation is 
strongly age-related. This suggests that previous reports in ecological studies or 
substantively smaller studies using pedigrees or relatively small numbers of genetic markers 
may have been false positives5,6. The lack of directional dominance on these traits does not, 
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however, rule out a recessive component, as recessive variants acting in different directions 
will cancel out. Dominance variance is predicted to be greater for late-onset fitness traits26, 
so the lack of genome-wide homozygosity effects in the cardio-metabolic traits may be due 
to lack of directional dominance. ROH analyses within specific genomic regions are 
warranted to map recessive effects even when there is no genome-wide directional 
dominance. Such recessive effects have been observed for a subset of cardiovascular risk 
factors27 and expression traits28.
We have demonstrated the existence of directional dominance on four complex traits 
(stature, lung function, cognitive ability and educational attainment) whilst showing any 
effect on the other 12 health-related traits is at least almost an order of magnitude smaller or 
non-existent. This directional dominance implies that size and cognition (like schizophrenia 
protective alleles29) have been positively selected in human history – or at least that some 
variants increasing these traits contribute to fitness. However, the lack of any evidence for 
an association between many late onset cardiovascular disease risk factors and ROH is 
perhaps surprising and suggests testing directly for an association between ROH and disease 
outcome. The magnitude of genome-wide homozygosity effects is relatively small in all 
cases, thus Darwin’s supposition30 of “any evil [of inbreeding] being very small” is 
substantiated.
METHODS
Outline
Our aim was to look for an association between a genetic effect (SROH) and 16 complex 
traits. Our approach followed best practice genome-wide association meta-analysis 
(GWAMA) protocols, where applicable, except we had only one genetic effect to test.
Cohorts were invited to join based on known previous participation in GWAMA and 
willingness to participate. 159 sub-cohorts were created from 102 population-based or case-
control genetic studies, by separating different genotyping arrays, cases and controls or 
ethnic sub-groups to ensure each sub-cohort was homogeneous. Within each of the 159 sub-
cohorts we measured the association between SROH and trait using the following model. 
Where a sub-cohort had been ascertained on the basis of a disease status associated with a 
particular trait, that sub-cohort was excluded from the corresponding trait analysis.
Phenotype was regressed on genetic effect and known relevant covariates within each 
cohort, under the model specified in Equation 1. The estimated genetic effect of SROH was 
then meta-analysed using inverse variance meta-analysis.
Equation (1)
Where Y is the vector of trait values, μ the intercept, b1 the effect of SROH and b2-6 the 
effect of covariates. PC1 – PC3, the post quality control within-cohort principal components 
of the cohort’s relationship matrix and e the residual. Relationship matrices were determined 
genomically by each cohort using genome wide array data. In addition, any other cohort-
specific covariates known to be associated with the trait, including further principal 
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components, and any trait-specific covariates and stratifications, such as medication and 
smoking status, were fitted as specified below. SROH was the sum of ROH called, with a 
length of at least 1.5 Mb using PLINK31.
As is routine in GWAMA, for family-based studies only, we also fitted an additional term to 
account for additive genetic values and relatedness, using grammar+ type residuals and full 
hierarchical mixed modeling using GenABEL32 and hglm33, as specified in equation 2.
Equation (2)
Where a is the additive genetic value of each individual. Var(a) is assumed to be 
proportionate to the Genomic Relationship matrix (GRM) (a pedigree relationship matrix 
was used in the Framingham Heart Study) . Z is the identity matrix.
We then meta-analysed the regression coefficients (b1) of traits on SROH for the 159 
subcohorts.
Cohort Recruitment
Data from 102 independent genetic epidemiology studies of adults were included. All 
subjects gave written informed consent and studies were approved by the relevant research 
ethics committees. Homogeneous sub-cohorts were created for analysis on the basis of 
ethnicity, genotyping array or other factors. Where a cohort had multiple ethnicities, sub-
cohorts for each separate ethnicity were created and analysed separately. In all cases 
European-, African-, South or Central Asian-, East Asian- and Hispanic-heritage individuals 
were separated. In some cases sub-categories such as Ashkenazi Jews were also 
distinguished. Ethnic outliers were excluded, as were the second of any monozygotic twins 
and pregnant subjects. Continental ancestry of cohorts participating in each trait study is 
presented in Extended data Table 1. Cohort genotyping and summary information are shown 
in Supplementary Table 6, with age, sex, trait and homozygosity summary statistics given in 
Supplementary Tables 9,10,, and 11.For case-control and trait extreme studies, patients or 
extreme-only sub-cohorts were analysed separately to controls. Where case status was 
associated with the trait under analysis the sub-cohort was excluded from that study (see 
below).
Subjects within a sub-cohort were genotyped using the same SNP array, or where two very 
similar arrays were used (e.g. Illumina OmniExpress and IlluminaOmni1), the intersection 
of SNPs on both arrays – provided the intersection exceeded 250,000 SNPs. Where a study 
used two different genotyping arrays, separate subcohorts were created for each array, and 
analysis was done separately. Paediatric cohorts were not included.
Genotyping
All subjects were genotyped using high density genome-wide (>250,000 SNP) arrays, from 
Illumina, Affymetrix or Perlegen. Custom arrays were not included. Each study’s usual 
array-specific genotype quality control standards for genome-wide association were used 
and are shown in Supplementary Table 6. Only autosomal data were analysed.
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Phenotyping
We studied 16 quantitative traits which are widely available and represent different domains 
related to health, morbidity and mortality: height, body mass index (BMI), waist : hip ratio 
(WHR), diastolic and systolic blood pressure (DBP, SBP), fasting plasma glucose (FPG), 
fasting insulin (FI), Haemoglobin A1c (HbA1c), total-, HDL- and LDL-cholesterol, 
triglycerides, forced expiratory volume in 1 second (FEV1), ratio of FEV1 to forced vital 
capacity (FVC), general cognitive ability (g) and years of educational attainment (EA). 
Phenotypic QC was performed locally to assess the accuracy and distribution of phenotypes 
and covariates. Further covariates were included when the relevant GWAS consortium also 
included them. The trait categories were anthropometry, blood pressure, glycaemic traits, 
classical lipids, lung function, cognitive function and educational attainment, following 
models in the GIANT34, ICBP35, MAGIC36, CHARGE37, Spirometa38 and SSGAC39 
consortia. The model for FEV1 did not include height as a covariate. Effect sizes for FEV1 
therefore include size effects that also underpin height. Studies assembled files containing 
study traits and the following covariates: sex, age, first three principal components of 
ancestry, lipid-lowering medication, ever-smoker status, anti-hypertensive medication, 
diabetes status and year of birth (YOB). Educational attainment was defined in accordance 
with the ISCED 1997 classification (UNESCO), leading to seven categories of educational 
attainment that are internationally comparable39. LDL values estimated using Friedewald’s 
equation were accepted. Cohorts without fasting samples did not participate in the LDL-
cholesterol, triglycerides, fasting insulin or fasting plasma glucose analyses. Cohorts with 
semi-fasting samples fitted a categorical or quantitative fasting time variable as a covariate. 
Subjects with less than 4 hours fasting were not included.
Where subjects were ascertained, for example, on the basis of hypertension, that sub-cohort 
was excluded from analysis of traits associated with the disorder, for example blood 
pressure. The traits excluded from meta-analysis are as follows: ascertainment on type-2-
diabetes, thus fasting insulin, HbA1c, fasting plasma glucose excluded; ascertainment on 
hypertension, thus blood pressures excluded; ascertainment on venous thrombosis or 
coronary artery disease, thus blood lipids excluded; ascertainment on obesity or the 
metabolic syndrome, thus blood lipids, body mass index, waist-hip ratio, fasting insulin and 
fasting plasma glucose excluded.
Somewhat unusually for a large consortium meta-analysis, the majority of the analysis after 
initial genotype and phenotype QC was performed by a pipeline of standardised R and shell 
scripts, to ensure uniformity and reduce the risk of errors and ambiguities (available at 
https://www.wiki.ed.ac.uk/display/ROHgen/Analysis+Plan+production+release+3.0). The 
pipeline was used for all stages from this point onwards.
Calling Runs of Homozygosity
SNPs with more than 3% missingness across individuals or with a minor allele frequency 
less than 5% were removed. ROH were defined as runs of at least 50 consecutive 
homozygous SNPs spanning at least 1500 kb, with less than a 1000 kb gap between adjacent 
ROH and a density of SNP coverage within the ROH of no more than 50 kb/SNP, with one 
heterozygote and 5 no calls allowed per window, and were called using PLINK31, with the 
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following settings --homozyg-window-snp 50 --homozyg-snp 50 --homozyg-kb 1500 --
homozyg-gap 1000 --homozyg-density 50 --homozyg-window-missing 5 --homozyg-
window-het 1. The same criteria were used by McQuillan et al.3, except SNP density has 
been relaxed to avoid regions of sparser coverage (still including 50 SNPs) being missed. 
The sum of runs of homozygosity was then calculated (SROH) . F was calculated as SROH/
(3×109 ROH ) reflecting the length of the autosomal genome. Copy number variants (CNV) 
are known to influence cognition40; however, prior calling of CNV and ROH in one of our 
cohorts reduced the SROH by only 0.3%3, making it implausible that deletions called as 
ROH influence our findings.
ROH called from different genotyping arrays
We show that SROH called with these parameters is relatively insensitive to the density and 
type of array used (Extended data Fig. 7). We used 2.5 million SNPs available for 851 
HapMap and 1000 Genomes Project41 samples from multiple continents to investigate the 
effect of array when using our ROH-calling parameters in plink. The dataset included 
samples of African, European, admixed American, South and East Asian heritage. By 
subsampling SNPs from the 2.5 million we created array data for the commonly used 
Illumina CNV370 and OmniExpress beadchips and the Affymetrix6 array for each 
individual (see Supplementary Table 7 for details of the SNP numbers). The correlation in 
SROH using different arrays on the same individuals was 0.93-0.94 for all pairwise chip 
comparisons.
Trait association with SROH
The association between trait and SROH was calculated using a linear model in accordance 
with equation 1. Additional covariates were fitted for some analyses (shown below) or for 
some cohorts where analysts were aware of study specific effects (e.g. study centre). For 
BMI, WHR, FEV1, FEV1/FVC and g, trait residuals were calculated for the model 
excluding SROH, these residuals were then rank-normalised and the effect of SROH on 
these rank-normalised residuals estimated. Triglycerides and fasting insulin were natural log 
transformed. Additional covariates were as follows: age2 was included as a covariate for all 
traits apart from height and g. BMI was included as a covariate for WHR, SBP, DBP, FPG, 
FI and HbA1c. YOB was included as a covariate for educational attainment and ever-
smoking for FEV1 and FEV1/FVC. Where a subject was known to be taking lipid-lowering 
medication, total cholesterol was adjusted by dividing by 0.8. Similarly, where a subject was 
known to be taking anti-hypertensive medication, SBP and DBP measurements were 
increased by 15 and 10 mm Hg, respectively.
Where the cohort was known to have significant kinship, genetic relatedness was also fitted, 
using the mixed model, in accordance with equation 2. The polygenic model was fitted in 
GenABEL using the fixed covariates and the genomic relationship matrix32. GRAMMAR+ 
(GR+) (ref. 42) residuals were then fitted to SROH as well as the full mixed model being 
fitted simultaneously, using GenABEL’s hierarchical generalised linear model (HGLM) 
function33. Populations with kinship thus potentially had three estimates of βFROH: using 
fixed effects only, and using the mixed model approaches, (GR+ and HGLM) for SROH.
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To investigate potential confounding, where available, EA was added as an ordinal covariate 
and all models rerun, giving revised estimates of βFROH. This is potentially an over 
adjustment for g due to the phenotypic and genetic correlations with EA43. However it must 
be recognised that EA does not capture all potential environmental confounding.
Cohort phenotypic means and standard deviations were checked visually for inter-cohort 
consistency, with apparent outliers then being corrected (e.g. due to units or incorrectly 
specified missing values), explained (e.g. due to different population characteristics) or 
excluded. Individual sub-cohort trait means and standard deviations are tabulated in 
Supplementary Table 9 and age and gender information is in Supplementary Table 10.
Meta-analysis
Again as is routine in GWAMA, analysis was performed within homogeneous sub-
populations and only meta-analysis of the estimated (within population) effect sizes was 
used to combine results between populations, avoiding any confounding effects of inter-
population differences in trait or genetic effect distributions. Inverse-variance meta-analysis 
of all sub-cohorts’ effect estimates was performed using Rmeta, on a fixed effect basis 
(Supplementary Table 5 compares random effects meta-analysis). In the principal analyses, 
for cohorts with relatedness, HGLM estimates of βFROH were preferred, however where 
HGLM had failed to converge, results using GRAMMAR+ were included. These results 
were combined with those for unrelated cohorts on a fixed model only basis. Result outliers 
were defined as individual cohort by trait results, which failed the hypothesis, cohort 
(βFROH) = pre-QC meta-analysis (βFROH), with a t-test statistic >3. Analyses were 
performed with and without outliers for βFROH in phenotypic units and in intra-sex 
phenotypic standard deviations (Supplementary Table 8). The principal results we present 
are for FROH with outliers included for the hypothesis tests (which turns out to be more 
conservative), but with outliers excluded when estimating βFROH (ref. 44). Meta-analysis 
was performed using inverse variance meta-analysis in the R package Rmeta, with βFROH 
taken as a fixed effect and alternatively as a random effect. The principal results are on a 
fixed effects basis, with Supplementary Table 5 showing comparison with the random 
effects analysis.
Meta-analyses were rerun for various subsets, according to geographic and demographic 
features of the cohorts. Cohorts were divided into more homozygous and less homozygous 
strata with the boundary being set so each within-stratum meta-analysis had equal statistical 
power.
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Extended Data
Extended Data Figure 1. Forest plot for cognitive g
Individual sub-cohort estimates of effect size and the standard error are plotted. Sub-cohorts 
are ordered from top to bottom according to their weight in the meta-analysis, so larger or 
more homozygous cohorts appear towards the top. The scale of beta FROH is in intra-sex 
standard deviations. The meta-analytical estimate is displayed at the bottom. Sub-cohort 
names follow the conventions detailed in Supplementary Table 6 and the Supplementary 
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Table 11 legend. Sample sizes, effect sizes and P values for association are given in Table 1. 
This trait was rank transformed.
Extended Data Figure 2. Forest plot for educational attainment
Individual sub-cohort estimates of effect size and the standard error are plotted. Subcohorts 
are ordered from top to bottom according to their weight in the meta-analysis, so larger or 
more homozygous cohorts appear towards the top. The scale of beta FROH is in intra-sex 
standard deviations. The meta-analytical estimate is displayed at the bottom. Sub-cohort 
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names follow the conventions detailed in Supplementary Table 6 and the Supplementary 
Table 11 legend. Sample sizes, effect sizes and P values for association are given in Table 1.
Extended Data Figure 3. Forest plot for height
Individual sub-cohort estimates of effect size and the standard error are plotted. Subcohorts 
are ordered from top to bottom according to their weight in the meta-analysis, so larger or 
more homozygous cohorts appear towards the top. The scale of beta FROH is in intra-sex 
standard deviations. The meta-analytical estimate is displayed at the bottom. Sub-cohort 
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names follow the conventions detailed in Supplementary Table 6 and the Supplementary 
Table 11 legend. Sample sizes, effect sizes and P values for association are given in Table 1.
Extended Data Figure 4. Forest plot for forced expiratory lung volume in one second
Individual sub-cohort estimates of effect size and the standard error are plotted. Subcohorts 
are ordered from top to bottom according to their weight in the meta-analysis, so larger or 
more homozygous cohorts appear towards the top. The scale of beta FROH is in intra-sex 
standard deviations. The meta-analytical estimate is displayed at the bottom. Sub-cohort 
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names follow the conventions detailed in Supplementary Table 6 and the Supplementary 
Table 11 legend. Sample sizes, effect sizes and P values for association are given in Table 1. 
This trait was rank transformed.
Extended Data Figure 5. Signals of directional dominance are robust to stratification by 
geography or demographic history or inclusion of educational attainment as covariate
(a) Cohorts are divided by continental biogeographic ancestry (African (15 sub-cohorts), 
East Asian (5), South & Central Asian (10), Hispanic (3)), with Europeans being divided 
into Finns (13), other European isolates (self-declared, 23), and (non-isolated) Europeans 
(90). Meta-analysis was carried out for all subsets with 2000 or more samples available. 
Sample numbers are as follows: cognitive g, Eur isolate 6638, European 44,153; educational 
attainment, African 4811, Eur isolate 8032, European 55,549, Finland 9068; height, African 
21,500, E Asian 30,011, Eur isolate 23,116, European 228,813, Finland 30,427, Hispanic 
5469, SC Asian 13,523; FEV1, African 6604, Eur isolate 4837, European 49,223, Finland 
2340. βFROH is consistent across geography and in both isolates and more cosmopolitan 
populations. (b) Cohorts were divided into High and Low ROH strata of equal power and 
meta-analysis repeated – the effects are consistent across strata for all four traits. The mean 
SROH for the high and low strata are 13.4 and 4.3 Mb for cognitive g; 28.1 and 5.1 Mb for 
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education attained; 31.9 and 10.8 Mb for height; and 41.4 and 4.5 Mb for FEV1. (c) To 
assess the potential for socio-economic confounding, where available, educational 
attainment was included in the regression model (edu) and compared to a model without 
educational attainment (none) in the same subset of cohorts. The signals reduce slightly 
when the education covariate is included; the analysis is not possible for educational 
attainment as a trait. For cognitive g, numbers are 36847 and 36023 for edu and none; for 
height 131,614 and 120,945; and for FEV1, 15717 and 15425. The numbers differ because 
of missing individual educational data within cohorts. + indicates phenotype was rank 
transformed. FEV1, forced expiratory lung volume in one second; g is the general cognitive 
component (first unrotated principal component of test scores across diverse tests of 
cognition); SC Asian is South & Central Asian, E Asian is East Asian, trait units are intra-
sex standard deviations and the genomic measure is unpruned SROH.
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Extended Data Figure 6. Signals of directional dominance are robust to model choice
Meta-analytical estimates of effect size and standard errors are plotted for various models. 
Fixed indicates no mixed modelling was used, gr res indicates the GRAMMAR+ residuals 
were fitted and hglm indicates the full hierarchical generalised linear mixed model was used. 
+ indicates the phenotype was rank transformed; FEV1 is forced expiratory lung volume in 
one second; Cognitive g is the general cognitive factor. 15,355 subjects were used for 
cognitive g, 36,060 for educational attainment, 89,112 for height and 15,262 for FEV1.
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Extended Data Figure 7. Correlation in SROH for different genotyping arrays using HapMap 
populations
In panels (a) – (c), X and Y axes show SROH (sum of runs of homozygosity) from 0-30 Mb 
(30,000 kb). ill370: Illumina CNV370, aff6: Affymetrix6, illomni: Illumina OmniExpress. 
The graphs are shown for the specific plink call parameters used. (d) Sample numbers per 
continent are presented in a bar chart. AFR: African, AMR: Mixed American, ASN: East 
Asian, EUR: European, SAN: South Asian. Only samples with SROH below 30 Mb are 
plotted, to be conservative to the effect of outliers, which have very strongly correlated 
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estimates of SROH (r = 0.96-0.97 for comparisons including such very homozygous 
individuals). In these plots, the correlation between SROH called by the two arrays, r = 
0.93-0.94.
Extended data Table 1
Continental ancestry of cohorts participating in each 
trait study
The first number in each cell is the number of participants with that continental ancestry. 
The second number is the number of sub-cohorts. BP is blood pressure; FEV1 is forced 
expiratory lung volume in one second; FVC is forced vital lung capacity; FP is fasting 
plasma; HbA1c is haemoglobin A1c; HDL/LDL are High/low-density lipoprotein; g is the 
general cognitive factor (first unrotated principal component of test scores across diverse 
domains of cognition). S/C Asian is South & Central Asian.
African East Asian European Hispanic S/C Asian All
BMI 21689/15 29009/5 279400/117 7836/3 13464/10 351398/150
Cognitive g 1539/1 NA/NA 49559/22 - - 51098/23
Diastolic BP 17074/12 24200/5 204742/85 7284/3 12876/9 266176/114
Education Attained 4811/4 NA/NA 79576/42 - 338/1 84725/47
Fasting Insulin 6895/8 1603/1 72006/49 - 6303/5 86807/63
FEV1 6604/5 617/1 58089/27 825/1 - 66135/34
FEVl/FVC 6565/5 616/1 57888/27 822/1 - 65891/34
FP Glucose 8942/9 1615/1 122368/74 1938/1 6921/5 141784/90
HbAlc 6629/4 694/1 92732/31 4038/2 7509/4 111602/42
HDL Cholesterol 15099/13 10478/5 215621/92 4426/3 12508/9 258132/122
Height 20300/14 30011/5 281369/114 5469/2 13523/10 350672/145
LDL Cholesterol 13375/11 2503/2 172245/77 4340/3 11186/8 203649/101
Systolic BP 17023/12 24424/5 205253/85 7225/3 12859/9 266784/114
Total Cholesterol 15130/13 20187/5 209421/91 4491/3 11674/8 260903/120
Triglycerides 13886/12 2542/2 181526/84 2745/2 10688/7 211387/107
Waist-hip ratio 8182/7 2549/2 171753/73 1446/1 12598/9 196528/92
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Figure 1. Runs of Homozygosity by Cohort
The sum of runs of homozygosity (SROH) and the number of runs of homozygosity 
(NROH) are shown by sub-cohort. . Populations differ by an order of magnitude in their 
mean burden of ROH. There are clear differences by continent and population type both in 
the mean SROH, and the relationship between SROH and NROH.. SC.Asian is South & 
Central Asian, E.Asian is East Asian, Eur.Isolate is European isolates. The ten most 
homozygous cohorts are labelled: AMISH are the Old Order Amish from Lancaster County, 
Pennsylvania; HUTT, S-Leut Hutterites from South Dakota; NSPHS, North Swedish 
Population Health Study, 06 and 09 suffixes are different sampling years from different 
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counties in Northern Sweden; OGP, Ogliastra Genetic Park, Sardinia, Italy; Talana is a 
particular village in the region; FVG, Friuli-Venezia-Giulia Genetic Park, Italy, omni and 
370 suffices refer to subsets genotyped with the Illumina OmniX and 370CNV arrays; 
HELIC, Hellenic Isolates, Greece, from Pomak villages in Thrace, and CLHNS, Cebu 
Longitudinal Health and Nutrition Study in the Philippines.
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Figure 2. Effects of genome-wide homozygosity, βFROH, on 16 traits
Four phenotypes show a significant effect of burden of ROH: height (145 sub-cohorts), 
FEV1 (34), educational attainment (47) and general cognitive ability, g (23). HDL and total 
cholesterol are not significantly different from zero after correcting for 16 tests and no effect 
is observed for the other traits. To account for the different numbers of males and females in 
cohorts and marked effect of sex on some traits, trait units are intra-sex standard deviations. 
βFROH is the estimated effect of FROH on the trait, where FROH is the ratio of the SROH to 
the total length of the genome. 95% confidence intervals (CIs) are also plotted. + indicates 
Joshi et al. Page 35
Nature. Author manuscript; available in PMC 2016 January 23.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
phenotype was rank transformed, * indicates phenotype was log transformed. BMI, body 
mass index; BP, blood pressure; FP fasting plasma; HbA1c, haemoglobin A1c (glycated 
haemoglobin); FEV1, forced expiratory volume in one second; FVC, forced vital capacity; 
HDL, high density lipoprotein; LDL, low density lipoprotein.
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Table 1
Effects of genome-wide burden of runs of homozygosity on four traits
P-association is P value for association, P-heterogeneity is P value for heterogeneity in a meta-analysis 
between trait and unpruned FROH, βFROH-SD is the effect size estimate of FROH expressed in units of intra-sex 
phenotypic standard deviations and SE is the standard error. βFROH-units is the effect size estimate for FROH = 
1 expressed in the measurement units and SE the standard error. The P values for those traits showing 
evidence for association are calculated including 5 outlying cohort-specific effect size estimates (an outlier 
was defined as T-test statistic over 3 for the null hypothesis that the cohort effect size estimate equals the 
meta-analysis effect size estimate), which is conservative as the majority of these are in the opposite direction. 
Beta estimates however exclude these outliers, for which there is evidence of discrepancy, and should thus be 
more accurate. + indicates phenotype was rank transformed; FEV1 is forced expiratory lung volume in one 
second; g is the general cognitive factor (first unrotated principal component of test scores across diverse 
domains of cognition).
Phenotype Outliers Height FEV1+ Educational Attainment Cognitive g+
Subjects 354,224 64,446 84,725 53,300
P-association Included <1 × 10−300 2.1 × 10−6 1.8 × 10−10 2.5 × 10−10
P-heterogeneity Included 0.014 0.10 1.2 × 10−5 0.071
βFROH-SD Excluded −2.91 −3.48 −4.69 −4.64
SE βFROH-SD Excluded 0.21 0.73 0.58 0.73
βFROH-units Excluded −0.188 −2.2 −12.9 −4.64
SE βFROH-units Excluded 0.014 0.46 1.83 0.73
Units m litres years SD
First cousin offspring effect Excluded −1.2 −137 −9.7 −0.29
Units cm ml months SD
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